Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 10:26 PM ET

Biotechnology

Company Overview of Genocea Biosciences, Inc.

Company Overview

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel vaccines and immunotherapies to treat infectious diseases. The company uses its proprietary discovery platform, AnTigen Lead Acquisition System, to design vaccines and immunotherapies that act through T cell immune responses. Its lead product candidate is GEN-003, a therapeutic vaccine or immunotherapy that is in Phase II trials to treat genital herpes infections. It is also developing GEN-004, a Phase II vaccine for the prevention of pneumococcal infections; GEN-001 that is in pre-clinical product candidate for treating chlamydia prophylaxis; GEN-002, which is in pre-clinical stage for the treatment of HSV-...

100 Acorn Park Drive

5th Floor

Cambridge, MA 02140

United States

Founded in 2006

57 Employees

Phone:

617-876-8191

Key Executives for Genocea Biosciences, Inc.

Chief Executive Officer, President and Director
Age: 46
Total Annual Compensation: $393.6K
Chief Financial Officer and Secretary
Age: 40
Total Annual Compensation: $285.2K
Chief Medical Officer
Age: 63
Total Annual Compensation: $366.1K
Senior Vice President of Research
Age: 43
Total Annual Compensation: $238.3K
Compensation as of Fiscal Year 2014.

Genocea Biosciences, Inc. Key Developments

Genocea Biosciences, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months June 30, 2015

Genocea Biosciences, Inc. announced unaudited consolidated earnings results for the second quarter and six months June 30, 2015. For the quarter, the company reported grant revenue of $115,000. Loss from operations was $10,026,000 compared to $6,909,000 a year ago. Net loss attributable to common stockholders was $10,314,000 or $0.43 per basic and diluted share compared to $7,146,000 or $0.41 per basic and diluted share a year ago. For the six months, the company reported grant revenue of $236,000. Loss from operations was $21,803,000 compared to $13,282,000 a year ago. Net loss attributable to common stockholders was $22,398,000 or $1.04 per basic and diluted share compared to $14,655,000 or $1.08 per basic and diluted share a year ago.

Genocea Biosciences, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Genocea Biosciences, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Genocea Announces Positive Top-Line Phase 2 Data for Genital Herpes Immunotherapy GEN-003

Genocea Biosciences, Inc. announced positive top-line data from a Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. During the 28-day observation period immediately after completion of dosing, the best dose of 60 µg per protein /75 µg of Matrix-M2TM adjuvant demonstrated a highly statistically significant (p<0.0001) 55% reduction from baseline in the viral shedding rate, the primary endpoint of the trial and a measure of anti-viral activity. All dose combinations tested, including the successful 30 µg per protein /50 µg of adjuvant dose from the prior Phase 1/2a trial, demonstrated a statistically significant viral shedding rate reduction versus baseline and only the lowest dose combination did not demonstrate a statistically significant reduction versus placebo. In a planned secondary analysis to assess impact on patient-reported genital lesion rates, a self-assessed measurement of clinical disease, all dose groups, including the placebo group, demonstrated a statistically significant reduction from baseline. The Phase 2 study showed that GEN-003 was generally safe and well tolerated by patients, with no serious adverse events related to the vaccine. Safety data throughout the trial is monitored by an independent data safety monitoring board. Although reactogenicity increased with adjuvant dose, there was no difference in discontinuations in patient dosing due to adverse events across the different treatment arms.

Similar Private Companies By Industry

Company Name Region
SYMIC Biomedical, Inc. United States
AbGenomics International, Inc. United States
BIO-CAT, Inc. United States
CymoGen Dx, LLC United States
Sanofi Pasteur VaxDesign Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 20, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Genocea Biosciences, Inc., please visit www.genocea.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.